These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 27809848

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
    Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2016 Sep 13; 15(1):134. PubMed ID: 27624168
    [Abstract] [Full Text] [Related]

  • 3. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2017 May 11; 16(1):63. PubMed ID: 28490337
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y, Yamagishi SI.
    Curr Vasc Pharmacol; 2019 May 11; 17(4):411-420. PubMed ID: 29766812
    [Abstract] [Full Text] [Related]

  • 6. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T.
    Cardiovasc Drugs Ther; 2018 Feb 11; 32(1):73-80. PubMed ID: 29435776
    [Abstract] [Full Text] [Related]

  • 7. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Shigiyama F, Kumashiro N, Fuchigami A, Hirose T.
    Cardiovasc Diabetol; 2018 Jun 12; 17(1):86. PubMed ID: 29895330
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
    Kishimoto S, Kinoshita Y, Matsumoto T, Maruhashi T, Kajikawa M, Matsui S, Hashimoto H, Takaeko Y, Kihara Y, Chayama K, Goto C, Mohamad Yusoff F, Nakashima A, Noma K, Higashi Y.
    Am J Hypertens; 2019 Jun 11; 32(7):695-702. PubMed ID: 31045223
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
    Dell'Oro R, Maloberti A, Nicoli F, Villa P, Gamba P, Bombelli M, Mancia G, Grassi G.
    High Blood Press Cardiovasc Prev; 2017 Dec 11; 24(4):393-400. PubMed ID: 28608024
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
    Hirata T, Inukai K, Morimoto J, Katayama S, Ishida H.
    Prim Care Diabetes; 2014 Oct 11; 8(3):265-70. PubMed ID: 24530100
    [Abstract] [Full Text] [Related]

  • 15. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
    Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T.
    Drug Res (Stuttg); 2016 Jan 11; 66(1):18-22. PubMed ID: 26125284
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of the monotherapy of sitagliptin on glycemic control of patients with type 2 diabetes in different duration.
    Bai X, Li X, Li A, Wu L, Wang F, Geng J, Liu J, Bai X.
    Diabetes Metab Syndr; 2017 Dec 11; 11 Suppl 2():S821-S825. PubMed ID: 28734768
    [No Abstract] [Full Text] [Related]

  • 18. Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.
    Nakamura T, Iwanaga Y, Miyaji Y, Nohara R, Ishimura T, Miyazaki S, Sitagliptin Registry Kinki Cardiologists’ Study (SIRKAS) Investigators.
    Cardiovasc Diabetol; 2016 Mar 31; 15():54. PubMed ID: 27036865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.